EP 4398889 A1 20240717 - COMBINATION THERAPY
Title (en)
COMBINATION THERAPY
Title (de)
KOMBINATIONSTHERAPIE
Title (fr)
POLYTHÉRAPIE
Publication
Application
Priority
- US 202163242896 P 20210910
- US 202263300155 P 20220117
- US 202263301364 P 20220120
- US 202263403621 P 20220902
- US 2022043226 W 20220912
Abstract (en)
[origin: WO2023039249A1] The invention relates to methods of treating esophagogastic cancer in a subject in need thereof. The method comprising administering an effective amount of a combination of a DKK1 antibody, tislelizumab and one or more chemotherapeutic agents to the subject, wherein the subject either has a DKK-1 H-score of 35 or more or a DKK1 Tumor Percentage Score (TPS) of 20% or more and has not received prior systemic therapy for the esophagogastric cancer, or has a CPS of less than 5. The present invention also provides a pharmaceutical composition and a kit comprising a combination of a DKK1 antibody, tislelizumab and one or more chemotherapeutic agents.
IPC 8 full level
A61K 31/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP)
A61K 31/555 (2013.01); A61K 31/7068 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/18 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2023039249 A1 20230316; EP 4398889 A1 20240717; JP 2024533439 A 20240912
DOCDB simple family (application)
US 2022043226 W 20220912; EP 22786605 A 20220912; JP 2024515636 A 20220912